Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Cancer Genetics Inc (CGIX) USD0.0001

Sell:$2.42 Buy:$2.50 Change: $0.09 (3.83%)
Market closed |  Prices as at close on 27 November 2020 | Switch to live prices |
Change: $0.09 (3.83%)
Market closed |  Prices as at close on 27 November 2020 | Switch to live prices |
Change: $0.09 (3.83%)
Market closed |  Prices as at close on 27 November 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services and molecular markers. Through its subsidiary, the Company offers preclinical test systems. The Company offers discovery services to the pharmaceutical industry, biotechnology companies and academic research centers. The Company provides the tools and testing methods for companies and researchers to identify new molecular- and biomarker-based indicators for disease and to determine the pharmacogenomics, toxicity and efficacy of therapeutic candidate compounds. Its discovery services include development of both xenograft and syngeneic animal models, toxicology and genetic toxicology services, pharmacology testing, pathology services, and validation of biomarkers for diseases including cancers. It also provides consulting, guidance and preparation of samples.

Contact details

201 State Rt 17 Fl 2
United States
+1 (201) 5289200

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$9.58 million
Shares in issue:
4.07 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • John Roberts
    President, Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer
  • Jane Houldsworth
    Vice President - Research & Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.